In particular, MyD88 was reported to play a role in the occurrence and development of breast cancer [46], epithelial ovarian carcinoma [47], human hepatocellular carcinoma [48], osteosarcoma [49], adenocarcinoma of the colon [50], and hematopoietic cancer-like lymphoma and leukemia [45]. Here, MYD88 is linked to hematopoietic and lymphoid cell neoplasm.